CLINICAL TRIALS PROFILE FOR STROMECTOL
✉ Email this page to a colleague
All Clinical Trials for Stromectol
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00921154 ↗ | Ivermectin Solution Bioequivalence Study - Fasted | Completed | Johnson & Johnson Consumer and Personal Products Worldwide | Phase 1 | 2005-03-01 | The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of ivermectin solution 1 mg/ml with a marketed reference formulation of ivermectin 3 mg tablets when taken after an overnight fast .The study is designed in accordance with the EU Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2001. |
| NCT00921219 ↗ | Ivermectin Solution Bioequivalence Study - With Food (Repeat) | Completed | Johnson & Johnson Consumer and Personal Products Worldwide | Phase 1 | 2005-09-01 | The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of Ivermectin solution 1 mg/ml with a marketed reference formulation of Ivermectin 3 mg tablets when taken after a standard meal. The study is designed in accordance with the EU Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2001. |
| NCT00921674 ↗ | Ivermectin Solution Bioequivalence Study - With Food | Completed | Johnson & Johnson Consumer and Personal Products Worldwide | Phase 1 | 2005-02-01 | The purpose of this study was to compare the pharmacokinetic and bioavailability profile (rate and amount of absorption into the bloodstream) of a test formulation of Ivermectin solution 1 mg/ml with a marketed reference formulation of Ivermectin 3 mg tablets when taken after a standard meal. The study is designed in accordance with the EU Note for Guidance on the Investigation of Bioavailability and Bioequivalence 2001. |
| NCT01570504 ↗ | Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis | Completed | European Commission | Phase 3 | 2013-03-01 | Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite. Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis. |
| NCT01570504 ↗ | Multiple Versus Single Dose of Ivermectin for the Treatment of Strongyloidiasis | Completed | Centro per le Malattie Tropicali | Phase 3 | 2013-03-01 | Ivermectin is currently the best drug to cure strongyloidiasis, but the "standard" single dose of 200 mcg/kg is probably not enough to guarantee cure. As strongyloidiasis can be fatal in immunosuppressed patients, it is mandatory to define the optimal dosage to eradicate the parasite. Aim of this study is to define the most effective dose schedule of ivermectin to cure strongyloidiasis. |
| NCT02045069 ↗ | Efficacy and Safety of Ivermectin Against Dengue Infection | Unknown status | Ministry of Health, Thailand | Phase 2/Phase 3 | 2014-02-01 | This is a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Ivermectin in Children and Adult patients with Dengue Infection. |
| NCT02045069 ↗ | Efficacy and Safety of Ivermectin Against Dengue Infection | Unknown status | Mahidol University | Phase 2/Phase 3 | 2014-02-01 | This is a Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study of Efficacy and Safety of Ivermectin in Children and Adult patients with Dengue Infection. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Stromectol
Condition Name
Clinical Trial Locations for Stromectol
Trials by Country
Clinical Trial Progress for Stromectol
Clinical Trial Phase
Clinical Trial Sponsors for Stromectol
Sponsor Name
